BVAXF (BioVaxys Technology) Debt-to-Equity : -0.04 (As of Jan. 2025)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Debt-to-Equity?

BioVaxys Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2025 was $0.05 Mil. BioVaxys Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2025 was $0.00 Mil. BioVaxys Technology's Total Stockholders Equity for the quarter that ended in Jan. 2025 was $-1.21 Mil. BioVaxys Technology's debt to equity for the quarter that ended in Jan. 2025 was -0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioVaxys Technology's Debt-to-Equity or its related term are showing as below:

BVAXF' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.33 Med: -0.06 Max: -0.04
Current: -0.04

During the past 7 years, the highest Debt-to-Equity Ratio of BioVaxys Technology was -0.04. The lowest was -0.33. And the median was -0.06.

BVAXF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs BVAXF: -0.04

BioVaxys Technology Debt-to-Equity Historical Data

The historical data trend for BioVaxys Technology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Debt-to-Equity Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Debt-to-Equity

Get a 7-Day Free Trial

-0.04

BioVaxys Technology Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Debt-to-Equity	Get a 7-Day Free Trial															-0.07	-0.06	-0.32	-0.04	-0.04

Competitive Comparison of BioVaxys Technology's Debt-to-Equity

For the Biotechnology subindustry, BioVaxys Technology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVaxys Technology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

BioVaxys Technology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioVaxys Technology's Debt to Equity Ratio for the fiscal year that ended in Oct. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.049	+	0)	/	-1.396
	=	-0.04

BioVaxys Technology's Debt to Equity Ratio for the quarter that ended in Jan. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.047	+	0)	/	-1.211
	=	-0.04

BioVaxys Technology (OTCPK:BVAXF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BioVaxys Technology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.